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Abstract 
 
Efficacy of the combined use of bevacizumab and irinotecan in a human colorectal cancer xenograft 
model analysed by SPECT imaging 
 
Christel Vangestel, Christophe Van de Wiele, Geboes Karen, Laurent Stephanie, Nancy Van Damme, Marc 
Peeters 
 
Introduction: Colorectal tumors are dependent on angiogenesis for growth and VEGF is a key mediator of 
tumor angiogenesis. Antiangiogenic drugs can induce a transient normalization of the tumor vasculature and can 
thus potentiate the activity of co-administered chemotherapy. 
Aim: The efficacy of anti-human VEGF antibody (bevacizumab) with or without irinotecan was evaluated in a 
human colorectal cancer xenograft model. 
Methods: Colo205-bearing mice were treated with a single dose (ip) of bevacizumab (5mg/kg) 2, 4 or 6 days 
prior to administration of a single dose of irinotecan (100mg/kg) or 0.9% NaCl.  Microvessel density (MVD), 
collagen covered tumor vessels (Masson’s Trichrome staining), pericyt coverage (α-smooth muscle actin 
immunostaining) and tumor hypoxic fraction (Pimonidazole staining) was determined at the three different time 
points following treatment of bevacizumab. To investigate the possible synergistic effects of the combination 
therapy, the apoptosis-detecting radiotracer 
99m
Tc His-ann A5 was injected iv (0.5 mCi) in mice 12, 24 and 48 
hours after start of the irinotecan treatment and also to control mice (n=3 in each time group). MicroSPECT 
imaging was subsequently performed 3.5 hours after injection of the radiotracer. The results were correlated to 
histological analysis for apoptosis (caspase-3 activation).  
Results: MVD decreased significantly, α-smooth muscle actin and collagen covered vessels were increased 
compared to control tumors, 4 days after bevacizumab treatment, suggesting normalization of the tumor 
vasculature. Hypoxic fraction was slightly reduced 4 days after treatment with bevacizumab. SPECT analyses 
demonstrated a significant increase in tumoral 
99m
Tc His-ann A5 uptake 4 days after bevacizumab treatment and 
24h after irinotecan administration (180± 37% injected dose/ tumor volume, p < 0.05) compared to each 
monotherapy demonstrating a synergistic effect of both therapies. Quantitative 
99m
Tc-ann A5 tumor uptake 
correlated well with the number of apoptotic cells as determined by caspase-3 immunostaining (R
2
= 0.81, p = 
0.04). 
Conclusion: Four days after administration, VEGF inhibition with bevacizumab normalizes the tumor 
vasculature in the Colo205 model, leading to an improved cytotoxic effect of irinotecan. 
